TY - JOUR
T1 - Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19
T2 - A Systematic Review and Meta-Analysis
AU - Qu, Wenchun
AU - Wang, Zhen
AU - Engelberg-Cook, Erica
AU - Yan, Dan
AU - Siddik, Abu Bakar
AU - Bu, Guojun
AU - Allickson, Julie G.
AU - Kubrova, Eva
AU - Caplan, Arnold I.
AU - Hare, Joshua M.
AU - Ricordi, Camillo
AU - Pepine, Carl J.
AU - Kurtzberg, Joanne
AU - Pascual, Jorge M.
AU - Mallea, Jorge M.
AU - Rodriguez, Ricardo L.
AU - Nayfeh, Tarek
AU - Saadi, Samer
AU - Durvasula, Ravindra V.
AU - Richards, Elaine M.
AU - March, Keith
AU - Sanfilippo, Fred P.
N1 - Publisher Copyright:
© 2022 Published by Oxford University Press.
PY - 2022/7
Y1 - 2022/7
N2 - MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-Analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, IâŠâŠ2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, IâŠâŠ2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.
AB - MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-Analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, IâŠâŠ2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, IâŠâŠ2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.
KW - COVID
KW - MSC
KW - cytokine storm
KW - hospital recovery
KW - pulmonary
UR - http://www.scopus.com/inward/record.url?scp=85133141402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133141402&partnerID=8YFLogxK
U2 - 10.1093/stcltm/szac032
DO - 10.1093/stcltm/szac032
M3 - Article
C2 - 35640138
AN - SCOPUS:85133141402
SN - 2157-6564
VL - 11
SP - 688
EP - 703
JO - Stem Cells Translational Medicine
JF - Stem Cells Translational Medicine
IS - 7
ER -